# **RESEARCH ARTICLE**

ARTICLE HISTORY

10.2174/1567205019666220128120927

This is an Open Access article published

https://creativecommons.org/licenses/

CrossMark

Received: March 21, 2021

Revised: December 4, 2021

Accepted: January 13, 2022

under CC BY 40

by /4.0/legalcode

DOI.



Random-Forest-Algorithm-Based Applications of the Basic Characteristics and Serum and Imaging Biomarkers to Diagnose Mild Cognitive Impairment



Juan Yang<sup>1,2</sup>, Haijing Sui<sup>3</sup>, Ronghong Jiao<sup>4</sup>, Min Zhang<sup>5</sup>, Xiaohui Zhao<sup>5</sup>, Lingling Wang<sup>6</sup>, Wenping Deng<sup>7</sup> and Xueyuan Liu<sup>1,\*</sup>

<sup>1</sup>Department of Neurology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, People's Republic of China; <sup>2</sup>Department of Neurology, Shanghai Pudong New Area People's Hospital, Shanghai, 201299, China; <sup>3</sup>Department of Radiology, Shanghai Pudong New Area People's Hospital, Shanghai, People's Republic of China; <sup>4</sup>Department of Clinical Laboratory, Shanghai Pudong New Area People's Hospital, Shanghai, People's Republic of China; <sup>5</sup>hcit.ai Co., Shanghai, People's Republic of China; <sup>6</sup>Department of Neurology, Shanghai, People's Republic of China; <sup>6</sup>Department of Neurology, Shanghai, People's Republic of China; <sup>6</sup>Department of Neurology, Shanghai, People's Republic of China; <sup>6</sup>Lepartment of Neurology, Shanghai, People's Republic of China; <sup>7</sup>Huawei Technology, Neurology, Shanghai, People's Republic of China; <sup>8</sup>Lepartment, Shanghai, People's Republic of C

**Abstract:** *Background*: Mild cognitive impairment (MCI) is considered the early stage of Alzheimer's Disease (AD). The purpose of our study was to analyze the basic characteristics and serum and imaging biomarkers for the diagnosis of MCI patients as a more objective and accurate approach.

*Methods*: The Montreal Cognitive Test was used to test 119 patients aged  $\geq$ 65. Such serum biomarkers were detected as preprandial blood glucose, triglyceride, total cholesterol, A $\beta$ 1-40, A $\beta$ 1-42, and *P*-tau. All the subjects were scanned with 1.5T MRI (GE Healthcare, WI, USA) to obtain DWI, DTI, and ASL images. DTI was used to calculate the anisotropy fraction (FA), DWI was used to calculate the apparent diffusion coefficient (ADC), and ASL was used to calculate the cerebral blood flow (CBF). All the images were then registered to the SPACE of the Montreal Neurological Institute (MNI). In 116 brain regions, the medians of FA, ADC, and CBF were extracted by automatic anatomical labeling. The basic characteristics included gender, education level, and previous disease history of hypertension, diabetes, and coronary heart disease. The data were randomly divided into training sets and test ones. The recursive random forest algorithm was applied to the diagnosis of MCI patients, and the recursive feature elimination (RFE) method was used to screen the significant basic features and serum and imaging biomarkers. The overall accuracy, sensitivity, and specificity were calculated, respectively, and so were the ROC curve and the area under the curve (AUC) of the test set.

**Results:** When the variable of the MCI diagnostic model was an imaging biomarker, the training accuracy of the random forest was 100%, the correct rate of the test was 86.23%, the sensitivity was 78.26%, and the specificity was 100%. When combining the basic characteristics, the serum and imaging biomarkers as variables of the MCI diagnostic model, the training accuracy of the random forest was found to be 100%; the test accuracy was 97.23%, the sensitivity was 94.44%, and the specificity was 100%. RFE analysis showed that age, A $\beta$ 1-40, and cerebellum\_4\_6 were the most important basic feature, serum biomarker, imaging biomarker, respectively.

**Conclusion:** Imaging biomarkers can effectively diagnose MCI. The diagnostic capacity of the basic trait biomarkers or serum biomarkers for MCI is limited, but their combination with imaging biomarkers can improve the diagnostic capacity, as indicated by the sensitivity of 94.44% and the specificity of 100% in our model. As a machine learning method, a random forest can help diagnose MCI effectively while screening important influencing factors.

Keywords: Machine learning, algorithms, cognitive dysfunction, diagnostic tool, mild cognitive impairment, screening.

\* Address correspondence to this author at the Department of Neurology, Shanghai Tenth People's Hospital Affiliated to Tongji University School of Medicine, 301 Yan Chang Road (M), Shanghai 200003, China; Tel: 20509000; E-mail: 13764032983@163.com

#### **1. INTRODUCTION**

Mild cognition impairment (MCI) is well recognized as the early stage of Alzheimer's Disease (AD) [1-3]. Especially, about 38.2% of MCI patients developed AD within 5-10 years, while 2017 meta-analysis demonstrated that 5-15% of those aged over 65 and had MCI (amnestic MCI) developed AD every year [4, 5]. With aging, the incidence rate of MCI grows higher, the prevalence rate of aMCI in people aged  $\geq$ 60 being approximately 17%-25% in different countries [6-9]. It is important that screening be conducted for MCI; however, up till now, the diagnostic method of MCI has taken the form of scale, which is known to be subjective and heterogeneous [10, 11].

Since the imaging and serum demographic characteristics have been considered the risk factors of MCI, researchers have never stopped pursuing the biomarkers of MCI, which indicate the progress to AD [12-14]. Neuroimaging biomarkers are considered promising as they are noninvasive and convenient [15]. The common neuroimaging biomarkers are found across different MRI modalities and sequences, such as Diffusion Tensor Imaging (DTI), Diffusion-Weighted Imaging (DWI), and Arterial Spin Labeling (ASL). As previously reported, DTI is used to examine the correlation between dynamic Vasomotor Reactivity (DVR), indicating the dysregulation of the cerebral microcirculation, which is considered an early cause of cognitive impairment [16]. DTI can help find microstructural changes; for example, reduced anisotropy always indicates MCI or the early stage of AD [17, 18].

Gyebnár et al. found that when voxel-wise and region of interest (ROI) analyses of fractional anisotropy (FA) were performed with ANOVA, FA was found to be lower in white matter ROI of individuals with MCI and that as logistic regression showed, measuring FA of the crus of fornix along grey matter volumetry improved the discrimination of aMCI from non-MCI individuals [17]. Tu et al. concluded that FA measures appeared to be more sensitive DTI parameters than MD values in detecting microstructural changes between subjective cognitive decline and MCI, suggesting that MCI had significant inverse correlations with FA value within the genu of the corpus callosum and left forceps minor and that based on regression analysis, MCI was best predicted by the FA value within the left forceps minor [19]. Ray et al. evaluated the regional alterations in the ADC of cortical gray and white matter and subcortical structures, which are known to be involved in MCI, stating that ADC from gray and white matter of different brain regions could be analyzed by applying an automated template-masking method in conjunction with a skeleton-based region competition segmentation algorithm [20]. Moreover, DTI-based network measures were found to be novel predictors of AD progression [21], which supports the evidence that the vascular mechanism is considered as an underlying component of cognitive impairment [22]. Recently, new mathematical methods have been proposed to utilize multi-modality MRI imaging to identify the potential imaging biomarkers of MCI or pre-AD, such as binary network matrices derived from DWI and DTI [23].

Considering serum biomarkers, some studies have suggested that elevated total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL-C) levels were the potential risk factor for cognitive impairment [24-27]. Glucose has also been considered the biomarker of MCI or AD [28, 29]. Considering the basic characteristics, age, gender, education, and hypertension are also regarded as the risk factors and biomarkers of MCI or AD [30-33]. However, fewer studies have explored why imaging and serum biomarkers and basic characteristics can be considered the best variables for diagnosing MCI. The purpose of our study was to apply the random-forest algorithm to analyze the basic characteristics and serum and imaging biomarkers to develop a better diagnostic model of MCI, which is to be more accurate and objective.

## 2. MATERIALS AND METHODS

## 2.1. Ethical Statement

This study was approved by the Medical Ethics Committee of Shanghai Pudong New Area People's Hospital, Shanghai, China (Prylz-2020-085). Written informed consent was obtained from all participants or their legally acceptable representatives.

## 2.2. Subject Recruitment

MCI was defined according to the following criteria: 1) cognitive concern or complaint by the subject, informant, nurse, or physician, with CDR 5 0.5; 2) objective impairment in at least 1 cognitive domain based on performance 1.5 SD below the mean using the norms obtained in the pilot study; 3) essentially normal functional activities, determined by the CDR and the ADL evaluation; and 4) absence of dementia, decided by DSM-IV.

For the study, all subjects were chosen from the local community. The Montreal Cognitive Assessment (MoCA) was used to assess MCI in individuals aged  $\geq 65$  without a medical history of schizophrenia, mental retardation, Parkinson's disease, stroke, or other medical conditions that could cause any problem to the assessment. Those defined as MCI patients and normal persons received MRI examinations based on their informed consent forms signed voluntarily. We excluded those who had vascular disease, Parkinson's disease, tumors, mental disorders, abnormal hearing and vision, and drug abuse based on history, MRI examination, and blood biomarker testing.

## 2.3. Medical and Neurological Examination

The questionnaire survey of MoCA/CDR/ADL and score calculation were performed by the five physicians who received unified training on MoCA-testing. The demographic data referred to age, gender, and medical history involving hypertension, diabetes, and heart disease. To begin with, the participants were screened by MoCA, with the score of 26 being the threshold of normal and MCI [34].

#### 2.4. MRI Examination

MRI 1.5T (GE Healthcare, WI, USA) examination was performed at the Department of Image, Shanghai Pudong New Area People's Hospital in Shanghai, China. The sequences included T1, DTI, ASL, and DWI. The indexes selected were fractional anisotropy (FA), cerebral blood flow (CBF), and apparent diffusion coefficient (ADC).

#### 2.5. Brain Imaging Segmentation

The skull-stripped images were obtained using the mixture models before registering to the Montreal Neurological Institute (MNI) space using the SyN method [35]. FA, ADC, and CBF median values were extracted from 116 brain regions using automated anatomical labeling parcellation (AAL) [36].

#### 2.6. Serum Examination

Whole blood after overnight fasting was collected from all participants using venipuncture; 4ml of blood was collected into an anticoagulant tube (BD vacutainer, USA), which was kept for 1h at room temperature (RT) before centrifuged at 1,000g for 10 mins at RT. The resultant supernatant (serum) was divided into 2 Eppendorf tubes (1ml each) to be temporarily stored at -80°C until examination. Eight components were selected for this study (A $\beta$ 1-40, A $\beta$ 1-42, P-tau, preprandial blood glucose, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL).

The enzyme-linked immunosorbent assay (ELISA)based techniques were used to assess serum  $A\beta$ 1-40/ $A\beta$ 1-42/P-tau. The serum levels of  $A\beta$ 1-40 (Cat. No: DAB140B, Sensitivity: 1.31-8.17pg/ml),  $A\beta$ 1-42 (Cat. No: DAB142, Sensitivity:0.762-4.73pg/ml), and *P*-tau (Cat. No: CSB-E17929h, Sensitivity:<7.8pg/ml) were quantified using commercial ELISA kits purchased from R&D Systems (MN, USA) according to the manufacturer's protocol. The concentrations of serum HDL/LDL/preprandial blood glucose were determined by a Cobas C501 automatic biochemistry analyzer using the enzymatic conversion method. The kit was supplied by the Roche Diagnostics GmbH (Mannheim, Germany).

#### 2.7. Random-forest Algorithm

All the data were randomly split into the training and test set. Recursive random forest algorithm, a method of supervised machine learning, was applied to the diagnosis of MCI, by screening the basic characteristics and significant biomarkers of serum and imaging using recursive feature elimination (RFE) as well as calculating the overall accuracy, sensitivity, and specificity by receiver operating characteristic curves (ROC) and areas under the curve (AUC) of the test set.

The diagnostic models of MCI based on the basic characteristics, serum biomarkers, and imaging biomarkers, separately and as a whole based on all the biomarkers involving the basic characteristics and serum and imaging biomarkers were established. We examined the superiority of the model in terms of accuracy, sensitivity, specificity, and AUC. Afterward, through RFE, we analyzed the significant basic characteristics and serum and imaging biomarkers in different models.

Random forest algorithm was implemented based on Anaconda, a Python-based data science platform.

## **3. RESULTS**

A total of 119 people aged over 65 were assessed by MO-CA before voluntarily being undergone MRI and serum examination. Of 119 subjects, 55 and 64 were placed under MCI and NC groups, respectively; a list of their basic characteristics was made (Table 1).

Table 1. The basic characteristics and serum biomarkers of MCI and NC groups.

-	MCI (N=55)	NC (N=64)
Gender (Female)	32 (43.8%)	40(54.8%)
Hypertension (Yes)	41(51.2%)	39 (48.8%)
Diabetes (Yes)	8 (57.1%)	6 (42.9%)
Coronary heart disease (Yes)	14 (60.9%)	9 (39.1%)
Age (year)	72±5.24	70.20±4.77
Fasting plasma glucose (mmol/l)	5.25±1.38	6.12±7.73
High density lipoprotein cholesterol (mmol/l)	1.43±0.45	1.45±0.42
Low density lipoprotein cholesterol (mmol/l)	2.37±0.82	2.54±0.82
Total cholesterol (mmol/l)	4.13±1.00	4.43±1.24
Triglycerides (mmolL)	1.27±0.82	1.34±0.80
Aβ1-40 (pg/ml)	171.93±90.45	141.58±49.31
Aβ1-42 (pg/ml)	58.69±87.03	38.49±37.06
P-tau (pg/ml)	177.77±78.30	175.46±98.37

With the brain regions segmented, 116 cerebral areas were extracted (Attached in accessory), accounting for FA value of DTI, ADC value of DWI, and CBF value of ASL. In the case of the basic characteristics as the variables of the diagnostic model of MCI, the random forest indicated training accuracy to be 96.38%, test accuracy to be 38.88%, sensitivity to be 63.15%, and specificity to be 58.82% with AUC=0.56. In the case of serum biomarkers as the variables of the diagnostic model of MCI, the random forest indicated training accuracy to be 100%, test accuracy to be 38.99%, sensitivity to be 44%, specificity to be 27.27% with AUC=0.35. In the case of the imaging biomarkers as the variables of the diagnostic model of MCI, the random forest indicated training accuracy to be 100%, test accuracy to be 86.23%, sensitivity to be 88.89%, and specificity to be 94.44% with AUC=0.97.

When the three sets of variables of the diagnostic model of MCI were combined, the random forest demonstrated training accuracy to be 100%, test accuracy to be 97.23%, sensitivity to be 94.44%, and specificity to be 100%. All ROC of the test set was achieved using the three sets of variables of the diagnostic model of MCI (Fig. 1).

According to the observation made on the importance of the basic characteristics as the variables of the diagnostic model of MCI, the random forest algorithm sorted an order: age > hypertension > education > gender > diabetes > coronary heart disease (Fig. 2). Considering the importance of serum characteristics, the random forest algorithm presented an order as:  $A\beta 1-42/1-40 > A\beta 1-42 > TAU > triglycerides >$  $A\beta 1-40 > LDL$  cholesterol (Fig. 3). In the case of the importance of imaging biomarkers, the random-forest algorithm presented an order as top ten imaging biomarkers: FA of left cerebellum\_4\_6, DWI of right insula, DWI of left olfactory, FA of left inferior frontal gyrus-opercular part, CBF of vermis\_7, DWI of the posterior cingulate gyrus, DWI of right fusiform, FA of the left rolandic operculum, DWI of right olfactory, and FA of left insula. Especially, FA of cerebellum\_4\_6\_L was the most important variable of the diagnostic model of MCI (Fig. 4).

### 4. DISCUSSION

Considering the scale-depended diagnostic method of MCI, which is known to be subjective and heterogeneous, our study aimed to pursue the biomarkers that could serve as a more objective approach to identifying MCI in aged individuals to develop a more effective diagnostic model of MCI.

In our study, we chose a random forest algorithm to analyze the basic characteristics and biomarkers of serum and imaging as the variables of our diagnostic model of MCI, investigating which variables were more accurate and reliable. Random-forest algorithm in virtue of a backward elimination random forest (BWERF) improved the accuracy because it used backward elimination to exclude the noise genes and aggregated the individual importance values to determine the transcription factors (TFs) retention [37]. Guo L et al. used a random-forest algorithm to analyze biomarkers to predict prognosis in the patients with hepatocellular carcinoma so that they developed the valuable model verified by external authentication [38]. Our findings also suggested that the diagnostic model of MCI based on a random-forest algorithm was accurate by sorting out the important variables of the diagnostic model.



Fig. (1). The ROC of different diagnostic models of MCI. (A higher resolution / colour version of this figure is available in the electronic copy of the article).



**Fig. (2).** The indexes sorted according to the importance in the model with basic characteristics. (A higher resolution / colour version of this figure is available in the electronic copy of the article).



Fig. (3). The indexes sorted according to the importance in the model with serum biomarkers. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

In our study, we screened out the basic characteristics, serum biomarkers, and imaging biomarkers using a random forest algorithm. The imaging biomarkers as the variables of the diagnostic model of MCI were found to be more accurate and reliable than the basic characteristics and serum biomarkers, with the sensitivity of 88.89% and the specificity of 94.44%. Moreover, when the three dimensions of basic characteristics and serum and imaging biomarkers were com-

bined, the diagnostic model of MCI came to be optimum, with the sensitivity of 94.44% and the specificity of 100%. The findings suggest that the random-forest algorithm can be quicker, more effective, and more accurate in screening out the diagnostic variables from many variables by sorting them into order according to the significance. This further suggests that in applying the random forest algorithm, the more variables the diagnostic model has, the better it will



Fig. (4). The indexes sorted according to the importance in the model with imaging biomarkers. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

be. Thus, it is safe to conclude that random forest algorithms can have superiority over the traditional statistical methodology in terms of diagnostic or prediction models.

In the current study, we analyzed through RFE the significant biomarkers of the basic characteristics, serum biomarkers, and imaging biomarkers in different models and found that in the diagnostic model of MCI in which we chose the basic characteristics as variables, the random forest algorithm helped sort out such an order of importance as age>hypertension> education > gender> diabetes> coronary heart disease. Although these demographic characteristics have been reported in different studies, in which they were considered intimate correlative with MCI or AD [28, 39-42], fewer research works have reported an order of importance. In the diagnostic model of MCI in which the serum biomarkers were chosen as variables, the random forest algorithm sorted out an order of importance as  $A\beta 1-42/1-40 > A\beta 1-42 >$ TAU > triglycerides > A $\beta$ 1-40 > LDL cholesterol. Serum Aß and P-tau and LDL cholesterol have been considered effective biomarkers of MCI or AD [43-45]; however, we further evaluated their importance through RFE.

Considering the imaging biomarkers in the current study, FA, ADC, and CBF median values were extracted from 116 brain regions using an automated anatomical labeling parcellation template, which differed from the traditional selection of image regions of interest (ROI), as indicated by its ability to obtain more comprehensive information about the whole brain, thus providing more accurate image information for machine learning and higher-quality image markers for the establishment of a diagnostic model. This could be ascribed to the use of brain image segmentation techniques. Thus, our random-forest-based diagnostic model of MCI was found to be highly sensitive and specific.

The top ten imaging biomarkers were found to be FA of left cerebellum 4 6, DWI of right insula, DWI of left olfactory, FA of left inferior frontal gyrus-opercular part, CBF of vermis 7, DWI of the posterior cingulate gyrus, DWI of right fusiform, FA of the left rolandic operculum, DWI of right olfactory, and FA of left insula. Especially, FA of cerebellum 4 6 L was found to be the most important variable of the current diagnostic model. The FA of the left cerebellum was considered as the most important imaging biomarker, suggesting that the FA impairment of the left cerebellum could be a significant indicator in MCI individuals, which to some extent corresponds with the previously reported findings that abnormal cerebellum was correlated with MCI [46], but different from AD in which the hippocampus was found to be impaired [47]. In general, hippocampus atrophy is accepted as an imaging biomarker for AD diagnosis [48]; however, in our study, the cerebellum 4 6 of the MCI patients was found to be altered. Thus, we hypothesized that the cerebellum 4 6 could be altered earlier than the hippocampal atrophy.

## CONCLUSION

Based on the random forest, the diagnostic model of MCI with imaging features as variables is found to be superior to the model with serum biomarkers and basic features. With the basic characteristics combined with the imaging and serum biomarkers, the diagnostic model of MCI is found to be optimum. The FA of left cerebellum through RFE is considered as the most important imaging biomarker. Moreover, the order of importance of the basic characteristics can be listed through RFE as age > hypertension > education > gender > diabetes > coronary heart disease, and the order of importance of the serum biomarkers is as follows:  $A\beta 1-42/1-40 > A\beta 1-42 > TAU > triglycerides > A\beta 1-40 > LDL cholesterol.$ 

#### LIMITATION

This was a small sample size study, which, to a great extent, made it a little difficult to obtain the serum and imaging biomarkers at the same time. Considering the diagnostic model, the validation was only internal, lacking external validation. The serum biomarkers were relatively fewer, which could show disadvantages when compared to the imaging ones as the features of the diagnostic model of MCI. Further investigations are needed to decide whether adding serum biomarkers could be useful as the serum-biomarker diagnostic model.

# **AUTHORS' CONTRIBUTIONS**

YJ conceived and designed the project. YJ performed all the experiments and wrote the manuscript. CGY performed the examination. DWP evaluated the random forest algorithm. ZM performed the brain imaging segmentation. All authors reviewed the manuscript.

## ETHICAL APPROVAL AND CONSENT TO PARTICI-PATE

This study was approved by the Medical Ethics Committee of Shanghai Pudong New Area People's Hospital, Shanghai, China (Prylz-2020-085).

# HUMAN AND ANIMAL RIGHTS

No animals were used in this study. All human procedures were followed in accordance with the guidelines of the Declaration of Helsinki.

#### **CONSENT FOR PUBLICATION**

Written informed consent was obtained from all participants or their legally acceptable representatives.

# AVAILABILITY OF DATA AND MATERIALS

Not applicable.

#### FUNDING

This study was supported by the Training Program for Academic Pioneers in Pudong New Area (No. PWRd2020-02) and Fund of Shanghai Municipal Health Commission (No. 202140101) and Multi-center clinical study of graded diagnosis and treatment of early cognitive dysfunction (No. 17411950100).

### ACKNOWLEDGEMENTS

Declared None.

## REFERENCES

- Farina FR, Pragulbickaitė G, Bennett M, *et al.* Contralateral Delay Activity is not a robust marker of cognitive function in older adults at risk of Mild Cognitive Impairment. Eur J Neurosci 2020; 51(12): 2367-75.
  - http://dx.doi.org/10.1111/ejn.14652 PMID: 31856354
- [2] Galasko D, Xiao M, Xu D, et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. Alzheimers Dement (N Y) 2019;

5(1): 871-82.

http://dx.doi.org/10.1016/j.trci.2019.11.002 PMID: 31853477

- [3] Hao X, Bao Y, Guo Y, et al. Multi-modal neuroimaging feature selection with consistent metric constraint for diagnosis of Alzheimer's disease. Med Image Anal 2020; 60: 101625. http://dx.doi.org/10.1016/j.media.2019.101625 PMID: 31841947
- [4] Knezevic D, Mizrahi R. Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment. Prog Neuropsychopharmacol Biol Psychiatry 2018; 80(Pt B): 123-31. http://dx.doi.org/10.1016/j.pnpbp.2017.05.007 PMID: 28533150
- [5] Shen T, Li Y, Wu P, Zuo C, Yan Z. Decision supporting model for one-year conversion probability from MCI to AD using CNN and SVM. Annu Int Conf IEEE Eng Med Biol Soc 2018; 2018: 738-41.
- http://dx.doi.org/10.1109/EMBC.2018.8512398 PMID: 30440502 [6] Wang T, Xiao S, Chen K, *et al.* Prevalence, incidence, risk and
- [6] wang 1, Xiao S, Chen K, et al. Trevalence, includine, insk and protective factors of annestic mild cognitive impairment in the elderly in Shanghai. Curr Alzheimer Res 2017; 14(4): 460-6. http://dx.doi.org/10.2174/1567205013666161122094208 PMID: 27875948
- [7] Hernandez JV. Prevalence of mild cognitive impairment and dementia in a population of adults over 60 years old in el salvador. J Alzheimer's Assoc 2017; 13(7): 842. http://dx.doi.org/10.1016/j.jalz.2017.06.1183
- [8] Wong MYZ, Tan CS, Venketasubramanian N, et al. Prevalence and risk factors for cognitive impairment and dementia in Indians: A multiethnic perspective from a singaporean study. J Alzheimers Dis 2019; 71(1): 341-51. http://dx.doi.org/10.3233/JAD-190610 PMID: 31381520
- [9] Miyake Y, Tanaka K, Senba H, et al. Hearing impairment and prevalence of mild cognitive impairment in Japan: Baseline data from the aidai cohort study in Yawatahama and Uchiko. Ear Hear 2020; 41(2): 254-8. http://dx.doi.org/10.1097/AUD.000000000000773 PMID:

31356389[10] Sanford AM. Mild cognitive impairment. Clin Geriatr Med 2017; 33(3): 325-37.

http://dx.doi.org/10.1016/j.cger.2017.02.005 PMID: 28689566

- [11] Raj V, Opie M, Arnold AC. Cognitive and psychological issues in postural tachycardia syndrome. Auton Neurosci 2018; 215: 46-55. http://dx.doi.org/10.1016/j.autneu.2018.03.004 PMID: 29628432
- [12] Crawford TJ, Taylor S, Mardanbegi D, et al. The effects of previous error and success in Alzheimer's disease and mild cognitive impairment. Sci Rep 2019; 9(1): 20204. http://dx.doi.org/10.1038/s41598-019-56625-2 PMID: 31882919
- [13] Perrotte M, Haddad M, Le Page A, Frost EH, Fulöp T, Ramassamy C. Profile of pathogenic proteins in total circulating extracellular vesicles in mild cognitive impairment and during the progression of Alzheimer's disease. Neurobiol Aging 2020; 86: 102-11. http://dx.doi.org/10.1016/j.neurobiolaging.2019.10.010 PMID: 31883770
- Soldan A, Pettigrew C, Zhu Y, et al. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease. Neurology 2020; 94(9): e950-60. http://dx.doi.org/10.1212/WNL.00000000008864 PMID: 31888969
- [15] Chiti A, Cecchi P, Pesaresi I, et al. Functional magnetic resonance imaging with encoding task in patients with mild cognitive impairment and different severity of leukoaraiosis. Psychiatry Res Neuroimaging 2018; 282: 126-31. http://dx.doi.org/10.1016/j.pscychresns.2018.06.012 PMID: 30539733
- [16] Marmarelis VZ, Shin DC, Tarumi T, Zhang R. Comparing model-based cerebrovascular physiomarkers with DTI biomarkers in MCI patients. Brain Behav 2019; 9(8): e01356. http://dx.doi.org/10.1002/brb3.1356 PMID: 31286695
- [17] Gyebnár G, Szabó Á, Sirály E, et al. What can DTI tell about early cognitive impairment? Differentiation between MCI subtypes and healthy controls by diffusion tensor imaging. Psychiatry Res Neuroimaging 2018; 272: 46-57. http://dx.doi.org/10.1016/j.pscychresns.2017.10.007 PMID: 29126669
- [18] Lo Buono V, Palmeri R, Corallo F, et al. Diffusion tensor imaging

of white matter degeneration in early stage of Alzheimer's disease: A review. Int J Neurosci 2020; 130(3): 243-50. http://dx.doi.org/10.1080/00207454.2019.1667798 PMID: 31549530

- [19] Tu MC, Lo CP, Huang CF, Huang WH, Deng JF, Hsu YH. Visual attention performances and related cerebral microstructural integrity among subjects with subjective cognitive decline and mild cognitive impairment. Front Aging Neurosci 2018; 10: 268. http://dx.doi.org/10.3389/fnagi.2018.00268 PMID: 30245626
- [20] Ray KM, Wang H, Chu Y, et al. Mild cognitive impairment: Apparent diffusion coefficient in regional gray matter and white matter structures. Radiology 2006; 241(1): 197-205. http://dx.doi.org/10.1148/radiol.2411051051 PMID: 16990677
- [21] Nir TM, Jahanshad N, Toga AW, et al. Connectivity network measures predict volumetric atrophy in mild cognitive impairment. Neurobiol Aging 2015; 36(1): S113-20. http://dx.doi.org/10.1016/j.neurobiolaging.2014.04.038 PMID: 25444606
- [22] Kim CM, Alvarado RL, Stephens K, et al. Associations between cerebral blood flow and structural and functional brain imaging measures in individuals with neuropsychologically defined mild cognitive impairment. Neurobiol Aging 2020; 86: 64-74. http://dx.doi.org/10.1016/j.neurobiolaging.2019.10.023 PMID: 31813626
- [23] Daianu M, Jahanshad N, Nir TM, et al. Rich club analysis in the Alzheimer's disease connectome reveals a relatively undisturbed structural core network. Hum Brain Mapp 2015; 36(8): 3087-103. http://dx.doi.org/10.1002/hbm.22830 PMID: 26037224
- [24] Liu Y, Zhong X, Shen J, et al. Elevated serum TC and LDL-C levels in Alzheimer's disease and mild cognitive impairment: A meta-analysis study. Brain Res 2020; 1727: 146554. http://dx.doi.org/10.1016/j.brainres.2019.146554 PMID: 31765631
- [25] Bahrami A, Barreto GE, Lombardi G, Pirro M, Sahebkar A. Emerging roles for high-density lipoproteins in neurodegenerative disorders. Biofactors 2019; 45(5): 725-39. http://dx.doi.org/10.1002/biof.1541 PMID: 31301192
- [26] Jiang Y, Zhu Z, Shi J, et al. Metabolomics in the development and progression of dementia: A systematic review. Front Neurosci 2019; 13: 343.
- http://dx.doi.org/10.3389/fnins.2019.00343 PMID: 31031585
  [27] Koch M, DeKosky ST, Goodman M, *et al.* High-density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. J Lipid Res 2020; 61(3): 445-54.
- http://dx.doi.org/10.1194/jlr.P119000473 PMID: 31892526
- [28] Jayaraj RL, Azimullah S, Beiram R. Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators. Saudi J Biol Sci 2020; 27(2): 736-50. http://dx.doi.org/10.1016/j.sjbs.2019.12.028 PMID: 32210695
- [29] Carbonell F, Zijdenbos AP, Bedell BJ. Spatially distributed amyloid-β reduces glucose metabolism in mild cognitive impairment. J Alzheimers Dis 2020; 73(2): 543-57.
- http://dx.doi.org/10.3233/JAD-190560 PMID: 31796668
  [30] Nebel RA, Aggarwal NT, Barnes LL, *et al.* Understanding the impact of sex and gender in Alzheimer's disease: A call to action. Alzheimers Dement 2018; 14(9): 1171-83.
- http://dx.doi.org/10.1016/j.jalz.2018.04.008 PMID: 29907423
  [31] Ibrahim A, Singh DKA, Shahar S. 'Timed Up and Go' test: Age, gender and cognitive impairment stratified normative values of older adults. PLoS One 2017; 12(10): e0185641.
- http://dx.doi.org/10.1371/journal.pone.0185641 PMID: 28972994
   [32] Ramanan VK, Castillo AM, Knopman DS, *et al.* Association of apolipoprotein E ε4, educational level, and sex with Tau deposition and tau-mediated metabolic dysfunction in older adults. JA-MA Netw Open 2019; 2(10): e1913909. http://dx.doi.org/10.1001/jamanetworkopen.2019.13909 PMID:
  - 31642932
- [33] Liu A, Sun Z, McDade EM, Hughes TF, Ganguli M, Chang CH. Blood pressure and memory: Novel approaches to modeling nonlinear effects in longitudinal studies. Alzheimer Dis Assoc Disord 2019; 33(4): 291-8.

http://dx.doi.org/10.1097/WAD.0000000000346 PMID: 31567145

[34] Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry 2018; 33(2): 379-88.

http://dx.doi.org/10.1002/gps.4756 PMID: 28731508

- [35] Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 2008; 12(1): 26-41.
- http://dx.doi.org/10.1016/j.media.2007.06.004 PMID: 17659998 [36] Rolls ET, Joliot M, Tzourio-Mazoyer N. Implementation of a new parcellation of the orbitofrontal cortex in the automated anatomical labeling atlas. Neuroimage 2015; 122: 1-5. http://dx.doi.org/10.1016/j.neuroimage.2015.07.075 PMID: 26241684
- [37] Deng W, Zhang K, Busov V, Wei H. Recursive random forest algorithm for constructing multilayered hierarchical gene regulatory networks that govern biological pathways. PLoS One 2017; 12(2): e0171532.
- http://dx.doi.org/10.1371/journal.pone.0171532 PMID: 28158291
  [38] Guo L, Wang Z, Du Y, *et al.* Random-forest algorithm based bio-
- [38] Guo L, wang Z, Du T, et al. Kandon-rotest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma. Cancer Cell Int 2020; 20(1): 251. http://dx.doi.org/10.1186/s12935-020-01274-z PMID: 32565735
- [39] Fu J, Liu Q, Du Y, et al. Age- and sex-specific prevalence and modifiable risk factors of mild cognitive impairment among older adults in China: A population-based observational study. Front Aging Neurosci 2020; 12: 578742.
- http://dx.doi.org/10.3389/fnagi.2020.578742 PMID: 33192471
- [40] Qin H, Zhu B, Hu C, Zhao X. Later-onset hypertension is associated with higher risk of dementia in mild cognitive impairment. Front Neurol 2020; 11: 557977. http://dx.doi.org/10.3389/fneur.2020.557977 PMID: 33324316
- [41] Maccora J, Peters R, Anstey KJ. What does (low) education mean in terms of dementia risk? A systematic review and meta-analysis highlighting inconsistency in measuring and operationalising education. SSM Popul Health 2020; 12: 100654. http://dx.doi.org/10.1016/j.ssmph.2020.100654 PMID: 33313373
- [42] Xia C, Vonder M, Sidorenkov G, et al. The relationship of coronary artery calcium and clinical coronary artery disease with cognitive function: A systematic review and meta-analysis. J Atheroscler Thromb 2020; 27(9): 934-58. http://dx.doi.org/10.5551/jat.52928 PMID: 32062643
- [43] Nam E, Lee YB, Moon C, Chang KA. Serum tau proteins as potential biomarkers for the assessment of Alzheimer's disease progression. Int J Mol Sci 2020; 21(14): E5007. http://dx.doi.org/10.3390/ijms21145007 PMID: 32679907
- [44] Abe K, Shang J, Shi X, et al. A new serum biomarker set to detect mild cognitive impairment and Alzheimer's disease by peptidome technology. J Alzheimers Dis 2020; 73(1): 217-27. http://dx.doi.org/10.3233/JAD-191016 PMID: 31771070
- [45] McFarlane O, Kozakiewicz M, Kędziora-Kornatowska K, et al. Blood lipids and cognitive performance of aging polish adults: A case-control study based on the PolSenior project. Front Aging Neurosci 2020; 12: 590546.
  - http://dx.doi.org/10.3389/fnagi.2020.590546 PMID: 33328967
- [46] Li Y, Liang Y, Tan X, et al. Altered functional hubs and connectivity in type 2 diabetes mellitus without mild cognitive impairment. Front Neurol 2020; 11: 1016. http://dx.doi.org/10.3389/fneur.2020.01016 PMID: 33071928
- [47] Yan S, Zheng C, Cui B, *et al.* Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2020; 47(10): 2440-52.
- http://dx.doi.org/10.1007/s00259-020-04752-8 PMID: 32157432
   [48] An N, Fu Y, Shi J, *et al.* Synergistic effects of APOE and CLU
- [48] An N, Fu Y, Sin J, et al. Synergistic effects of APOE and CLU may increase the risk of Alzheimer's disease: Acceleration of atrophy in the volumes and shapes of the Hippocampus and Amygdala. J Alzheimers Dis 2021; 80(3): 1311-27. http://dx.doi.org/10.3233/JAD-201162 PMID: 33682707